Classically, the AD biomarker profile consists of a reduction of Aβ42 peptide, a low Aβ42/40 ratio, as well as an increase in the levels of total tau and phosphorylated tau in cerebrospinal fluid (CSF) [33]. The gene discussed is MAPT; the disease is Alzheimer disease.